What is Spinogenix?
Spinogenix is dedicated to pioneering innovative therapies aimed at restoring and repairing synaptic connections within the brain. The company's core research focuses on tackling neurological, psychiatric, and neurodevelopmental disorders by addressing the root cause: the loss or dysfunction of synapses, rather than merely managing symptoms. Leveraging a proprietary platform and investigational small-molecule treatments, Spinogenix endeavors to enhance neuronal function and improve cognitive, behavioral, and motor outcomes for patients. This regenerative approach to brain health positions Spinogenix at the forefront of neurological care innovation.
How much funding has Spinogenix raised?
Spinogenix has raised a total of $10.6M across 1 funding round:
Private Equity
$10.6M
Private Equity (2026): $10.6M, investors not publicly disclosed
What's next for Spinogenix?
The substantial enterprise-level funding and recent strategic investment indicate that Spinogenix is poised for significant expansion and advancement in its clinical pipeline. This capital infusion is expected to accelerate the development of its investigational therapies, potentially enabling the company to move through critical clinical trial phases and towards regulatory submission. The focus on synaptic restoration suggests a long-term vision for transforming the treatment landscape for a wide array of brain-related conditions, positioning the company for future growth and potential market leadership in neurodegenerative and psychiatric therapeutics.
See full Spinogenix company page
